.gif) VIARTIS
|
|||||
|
PARKINSON'S DISEASE NEWS |
|||||
|
|
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].
14th December 2013 - News release ANTIBODIES FOR THE TREATMENT OF PARKINSON'S DISEASE
Roche and Prothena are collaborating to co-develop antibodies for the
treatment of Parkinson's Disease. Prothena's antibody for the
treatment of Parkinson's disease,
PRX002, targets alpha-synuclein. PRX002 is currently in
preclinical development. It is expected to enter Phase 1 clinical trials in
people with Parkinson's Disease in 2014. PRX002 has already been tested in
various cellular and animal models of synuclein-related disease.
|
|
|||
.gif) |
|||||
| ©2006-2014 Viartis | |||||
| 2015-08-08 22:26:28 | |||||
| [email protected] | |||||
Synuclein proteins are found throughout the
body. One protein from this family, alpha-synuclein, is found extensively in
neurons and characterize several neurodegenerative disorders, including Parkinson's
Disease, dementia with Lewy bodies, neurodegeneration with brain iron
accumulation type 1, and multiple system atrophy, which collectively are
termed synucleinopathies. As part of the agreement, Roche and Prothena will
initiate a research collaboration focused on including incorporation of
Roche's proprietary Brain Shuttle technology
to increase delivery of therapeutic antibodies to the brain.
For more information go to the
E-MAIL NOTIFICATION : If you would like to be
notified by e-mail when any new articles are added to Parkinson's Disease News, please merely
e-mail